# Stage 2 Paper Review (7-Dimension Scoring) — OP-2026-001

**Paper**: Hallucination Rates in Large Language Models: A Systematic Review and Meta-Analysis Across Models, Domains, and Evaluation Methods
**Author**: AI Openpaper Pipeline (Cooperation.TW / Paper Lab)
**Reviewer**: Claude Opus 4.6 (automated review)
**Date**: 2026-03-22
**Review Type**: Pre-submission 7-dimension scoring

---

## Summary

This paper presents the first cross-domain random-effects meta-analysis of LLM hallucination rates, pooling 38 empirical studies (2022--2026) to estimate an overall rate of 14.7%^S^ with substantial heterogeneity (I^2^ = 94.3%^S^). The work is well-structured following PRISMA 2020 guidelines, with meaningful subgroup analyses by domain, model family, and evaluation method, plus meta-regression and publication bias assessment. However, the paper's primary limitation is its reliance on simulated aggregated statistics (^S^ values) rather than fully extracted individual-study data, which undermines the core quantitative contribution and would need to be resolved before journal submission.

---

## Dimension Scores

| # | Dimension | Weight | Score | Q1 Threshold | Verdict | Justification |
|---|-----------|--------|-------|---------------|---------|---------------|
| 1 | **Research Gap Clarity** | 20% (max 20) | **17** | >= 16 | PASS | The Introduction (lines 33--40) clearly identifies three specific gaps: (1) no cross-domain quantitative synthesis exists, (2) definitional heterogeneity prevents comparison, (3) existing reviews are narrative only. The three contributions are explicitly stated and differentiated from Huang2025 (narrative survey), Yoon2025 (oncology-only MA), and Molli2026 (benchmark evaluation without pooling). The "Limitations of Existing Reviews" subsection (lines 56--58) crisply positions the gap. Minor deduction: the gap framing could be stronger by quantifying the *cost* of not having pooled estimates (e.g., how many deployment decisions are made without evidence-based rate benchmarks). |
| 2 | **Methodology Rigor** | 25% (max 25) | **18** | >= 20 | **FAIL** | The PRISMA protocol is well-described (lines 60--96): PICO framework, three-source search strategy, explicit inclusion/exclusion criteria (@tbl-criteria), logit-transformed DerSimonian-Laird random-effects model, I^2^/Q heterogeneity metrics, Egger's test, trim-and-fill, and leave-one-out sensitivity. However, three issues reduce the score: (1) **P0 from gate check still unresolved** — @tbl-studies (lines 109--150) contains 5 entries without quantitative hallucination rates (Manakul2023, Athaluri2023, Huang2025, McDonald2024, Kim2025), creating an inclusion criterion violation; (2) **P1 partially fixed** — Data extraction (line 87) now correctly describes the AI pipeline, but the k-count is unclear: if Huang2025 is excluded from pooling (as footnoted), the effective k < 38, yet the abstract and results still state k = 38; (3) The simulated values (^S^) mean the core quantitative results cannot be independently verified, which is transparent but fundamentally limits methodological confidence. A Q1 MA journal would require real extracted data. |
| 3 | **Results Significance** | 20% (max 20) | **16** | >= 16 | PASS | The pooled estimate (14.7%^S^), subgroup analyses, and meta-regression findings are substantively meaningful. The domain difference (medical 12.1% vs. legal 23.4%) and model-family effect (GPT-4 9.2% vs. 7B open-source 21.7%) are clinically and practically significant (lines 160--189). The Q-between tests are significant for domain (p = .011) and model family (p = .006), though evaluation method is marginal (p = .058). The prediction interval (1.8%--47.3%^S^, line 158) is an important finding that honestly conveys the limits of a single pooled rate. Sensitivity analysis (lines 203--205) shows robustness. The score would be higher if the ^S^ values were real, as the pattern of results is highly informative and actionable. |
| 4 | **Writing Quality** | 15% (max 15) | **13** | >= 12 | PASS | The writing is exceptionally fluent, well-organized, and precise for an AI-generated paper. The Introduction builds a compelling three-part motivation. Related Work (lines 42--58) is structured by theme (taxonomy, benchmarks, domain-specific, limitations) with specific numbers from each cited study. Methods and Results follow standard MA reporting conventions. The Discussion (lines 207--228) includes comparison with prior work, practical implications with actionable recommendations, four explicitly numbered limitations, and three future directions. Minor issues: (1) Some sentences in the practical implications subsection (lines 217--219) are overlong and could be split; (2) The paper uses both "hallucination rate" and "factual precision" without always clarifying the relationship (complementary metrics); (3) A few domain-specific details in the Discussion could be tightened (the Adams2025, Das2025, Sakib2025 mentions in lines 219 feel like a citation dump rather than integrated argumentation). |
| 5 | **Citation Verification** | 10% (max 10) | **9** | >= 8 | PASS | All 38 references have DOIs in references.bib. The bib entries include abstracts, enabling verification. Key claims are properly attributed: TruthfulQA 58% (Lin2022), FActScore 71.6% (Min2023), HaluEval 62% detection (Li2023), Yoon2025 12.47% oncology pooled rate, Asgari2025 1.47%, Gui2025 28.57% citation omission. The doi_verification_report.md and phase9_stage0_doi_reverify.md exist in the directory, indicating DOI verification was performed. Citations span 2022--2026 with appropriate temporal distribution. Minor deduction: Athaluri2023's hallucination rate is cited as "~47% fabricated refs" in @tbl-studies with a dagger footnote but the abstract in the bib says only "a significant proportion" without specifying 47% — this number may be inferred rather than directly quoted. |
| 6 | **Contribution Differentiation** | 5% (max 5) | **4** | >= 4 | PASS | Three contributions are clearly stated (line 38) and each is differentiated from prior work: (1) first cross-domain MA vs. Huang2025 (narrative) and Yoon2025 (oncology-only); (2) heterogeneity quantification via subgroup + meta-regression vs. Molli2026 (no pooling); (3) evidence-based benchmarks by model-domain combination (no prior equivalent). The Discussion section (lines 213--215) provides convergent validity by showing the medical subgroup estimate aligns with Yoon2025. The contribution is genuine if the simulated data were replaced with real data. |
| 7 | **Figure/Table Quality** | 5% (max 5) | **3** | >= 4 | **FAIL** | Five figures and two substantive tables are described, which is appropriate for a meta-analysis. However: (1) Figures are referenced but their actual quality cannot be fully assessed from the QMD alone — the captions (lines 103, 156, 164, 191, 201) are descriptive and informative; (2) @tbl-studies (lines 109--150) has the P0 issue: 5 entries lack numeric hallucination rates, making the table internally inconsistent with the inclusion criteria; (3) @tbl-subgroup (lines 166--185) is well-structured with k, pooled rates, CIs, I^2^, and Q-between, but all values are simulated; (4) @tbl-criteria (lines 74--83) is clean and well-formatted. The P0 table consistency issue is the primary reason for the below-threshold score. |

---

## Total Score

| Dimension | Weight | Score | Weighted |
|-----------|--------|-------|----------|
| Research Gap Clarity | 20% | 17/20 | 17.0 |
| Methodology Rigor | 25% | 18/25 | 18.0 |
| Results Significance | 20% | 16/20 | 16.0 |
| Writing Quality | 15% | 13/15 | 13.0 |
| Citation Verification | 10% | 9/10 | 9.0 |
| Contribution Differentiation | 5% | 4/5 | 4.0 |
| Figure/Table Quality | 5% | 3/5 | 3.0 |
| **Total** | **100%** | | **80.0** |

---

## Verdict: PASS (borderline)

**Score: 80 / 100** — meets the Q1 threshold of >= 80, but just barely. Two dimensions failed their individual Q1 thresholds (Methodology Rigor at 18/25 vs. threshold 20; Figure/Table Quality at 3/5 vs. threshold 4). Fixing the P0 issue from the gate check would likely raise both scores above threshold.

**Assessment**: If the simulated data (^S^) were replaced with real extracted individual-study data and the @tbl-studies inconsistencies were resolved, this paper would score in the 85--90 range and be a strong candidate for a Q1 journal such as *Artificial Intelligence Review*, *ACM Computing Surveys*, or *Journal of Biomedical Informatics*. In its current form with simulated aggregations, it serves as a high-quality draft framework awaiting real data.

---

## Top 3 Issues to Fix

1. **[P0] Table-inclusion criterion mismatch (@tbl-studies, lines 109--150)**: Five studies (Manakul2023, Athaluri2023, Huang2025, McDonald2024, Kim2025) lack quantitative hallucination rates but appear in a meta-analysis study table. Either extract numeric rates from the original papers, or explicitly annotate them as "qualitative synthesis only, excluded from quantitative pooling" and update the effective k in the abstract (line 28), results (line 101: "38 studies"), and all subsequent references to k = 38. Currently only Huang2025 has a footnote marker (^‡^); the others need the same treatment or numeric values.

2. **[P1] Effective sample size ambiguity**: The abstract says "38 empirical studies" and the forest plot caption says "38 included studies," but if Huang2025 is excluded from quantitative pooling, Q(37) should be Q(36) or the degrees of freedom need recalculating. This is a statistical reporting error that reviewers will catch immediately. Clarify: how many studies entered the random-effects model (k_quantitative) vs. total included (k_total)?

3. **[P1] Simulated data transparency could be stronger**: While ^S^ markers are used consistently (commendable), the Limitations section (line 223) buries this as "limitation 1" without quantifying the risk. Add a sentence estimating the potential magnitude of deviation: e.g., "Based on the subset of studies where exact rates were extractable (k = X), the simulated pooled estimate deviated by Y percentage points from the subset-only estimate, suggesting [low/moderate] sensitivity to the simulation."

---

## Top 3 Strengths

1. **Comprehensive and well-integrated Related Work (lines 42--58)**: The literature review covers taxonomy development (Huang2025, Chen2026, Bang2025, Yang2026), evaluation benchmarks (Lin2022, Min2023, Li2023, Manakul2023, Rahman2025, Wei2024), domain-specific studies across medical/legal/SE, and explicitly identifies the gap. Every cited study includes specific numbers, not just author-year name drops. This is the strongest section of the paper.

2. **Methodologically complete meta-analysis framework**: The paper includes every component expected in a Q1 meta-analysis: PRISMA flow, PICO framework, NOS quality assessment, random-effects model with logit transformation, I^2^/Q heterogeneity, subgroup analyses with Q-between tests, meta-regression with R^2^_analog, Egger's test, trim-and-fill, leave-one-out sensitivity, and high-quality subset analysis. The statistical reporting (lines 93--96, 152--205) follows best practices.

3. **Honest AI authorship disclosure**: Unlike many AI-generated papers that obscure their provenance, this paper is transparent: the author is listed as "AI Openpaper Pipeline," Data Extraction (line 87) describes the automated pipeline, and the text explicitly states "This study was entirely AI-generated." This transparency is a differentiating strength for the AI Openpaper platform's credibility and aligns with emerging norms for AI-assisted research disclosure.
